# Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

> **NCT02322775** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 211 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02322775
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-02
- **Primary completion:** 2015-10-07
- **Final completion:** 2015-10-07
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2017-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322775, "Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02322775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*